不同方案治疗多发性骨髓瘤120例疗效观察  

Efficacy of different treatment of 120 cases of multiple myeloma

作　　者：郑文宏 

机构地区：[1]景德镇市第三人民医院血液内科,景德镇333000

出　　处：《医药论坛杂志》2012年第1期34-35,38,共3页Journal of Medical Forum

摘　　要：目的探讨不同化疗方案对多发性骨髓瘤(MM)患者的治疗效果。方法回顾分析120例MM患者,其中40例患者接受沙利度胺加硼替佐米联合地塞米松(BD)方案治疗,40例患者接受沙利度胺加长春新碱联合阿霉素、地塞米松(VAO)方案化疗,另40例患者接受BD(硼替佐米联合地塞米松)方案治疗;所有患者均接受4～6个疗程治疗后进行全面评价,自动放弃治疗、疗程不符合标准以及失访患者不计入。结果沙利度胺+BD组、沙利度胺+VAD组和BD组的总完全缓解(TR)率分别为65%、40%和35%,3组比较差异均有显著性(P<0.05);3组的总体有效(RR)率分别为85%、62.5%和60%,3组比较差异无显著性(P>0.05)。常见的不良反应有骨髓抑制、消化道症状、肝肾功能损害、周围神经病变、乏力、血栓形成、血凝异常、带状疱疹病毒感染、精神症状、皮疹等,3组比较差异无显著意义(P>0.05)。结论沙利度胺加BD方案联合治疗MM具有不良反应少、耐受性好、疗效明显等优点。Objective To investigate the effect of the different chemotherapy regimens for multiple myeloma（MM） patient outcomes.Methods Retrospective analysis of 120 cases of MM patients,40 patients received thalidomide BD（bortezomib plus dexamethasone） regimen,40 patients received thalidomide and VAD（vincristine,adriamycin,to dexamethasone） regimen,and the other 40 patients received BD（bortezomib plus dexamethasone） treatment;All patients received 4-6 courses of treatment to conduct a comprehensive evaluation,automatic withdrawal of treatment,treatment does not meet the standards and lost patients not included.Results BD thalidomide group,thalidomide VAD group and the overall complete remission BD group（TR） rates were 65%,40% and 35%,three groups were significant differences（P0.05）;Three overall effective（RR） rates were 85%,62.5% and 60%,three groups no significant difference（P0.05）.Common adverse reactions are bone marrow suppression,gastrointestinal symptoms,liver and kidney dysfunction,peripheral neuropathy,fatigue,thrombosis,blood clotting abnormalities,herpes zoster virus infection,psychiatric symptoms,skin rash,three groups no significant difference（P0.05）.Conclusions Thalidomide treatment of MM BD program combined with fewer adverse reactions,well tolerated,efficacy and other advantages.

关 键 词：沙利度胺 VAD方案 BD方案 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]